LungLife AI Inc - California-based developer of clinical diagnostic solutions designed to address the early detection of lung cancer - Publishes performance results for blood-based LungLB test from a multi-site prospective study in patients with indeterminate pulmonary nodules.

The study was performed in collaboration with the MD Anderson Cancer Center in Houston, Texas, and the Icahn School of Medicine at Mount Sinai in New York. Its primary objective was to compare the LungLB test result with a lung biopsy diagnosis and assess performance in a patient cohort where commonly used nodule evaluation tools were not informative.

Chief Executive Officer Paul Pagano says: "We were excited to see that the LungLB performance remained strong in people who never smoked, because evidence has shown that the incidence of lung cancer in never smokers is increasing, and it is important new technologies address this expanding group. Additionally, LungLB was able to detect cancer in its earliest stages, which can be the most challenging to diagnose for doctors and most beneficial for patients."

Current stock price: 53.50 pence

12-month change: down 70%

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.